my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health.
Bioniche Life Sciences Inc. announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition. These patents have claims related to broad MCC compositions, pharmaceutical compositions and medicament compositions. The Japanese pa ... > more
Bioniche Life Sciences Inc. announced that its first Phase III clinical trial with a formulation of Mycobacterial Cell Wall-DNA Complex (MCC), trademarked Urocidin, for the treatment of bladder cancer, is progressing well. The Data Safety Monitoring Committee held its fifth scheduled meeti ... > more
Bioniche Life Sciences Inc. announced that an agreement has been reached with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure. This SPA agreement relates to the Company's pivotal Phase III study using its proprietary Mycobacterial Cell Wall- ... > more
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform
Bioniche Life Sciences Inc. announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition. These patents have claims related to broad MCC compositions, pharmaceutical compositions and medicament compositions. The Japanese pa ... more
Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well
Bioniche Life Sciences Inc. announced that its first Phase III clinical trial with a formulation of Mycobacterial Cell Wall-DNA Complex (MCC), trademarked Urocidin, for the treatment of bladder cancer, is progressing well. The Data Safety Monitoring Committee held its fifth scheduled meeti ... more
Bioniche Life Sciences Inc. announced that an agreement has been reached with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure. This SPA agreement relates to the Company's pivotal Phase III study using its proprietary Mycobacterial Cell Wall- ... more
© 1997-2020 LUMITOS AG, All rights reserved
